Ultragenyx Pharmaceutical (RARE) Liabilities and Shareholders Equity (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Liabilities and Shareholders Equity for 14 consecutive years, with $1.3 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 1.21% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $5.3 billion (down 10.83% YoY), while the FY2025 annual figure was $1.5 billion, up 1.93% from the prior year.
• Liabilities and Shareholders Equity slipped to $1.3 billion in Q1 2026 per RARE's latest filing, from $1.5 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.6 billion in Q3 2022 and bottomed at $1.2 billion in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2023.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity dropped 23.5% — and 2024, when it rose 24.25%.
• Ultragenyx Pharmaceutical's Liabilities and Shareholders Equity stood at $1.5 billion in 2022, then retreated by 3.52% to $1.5 billion in 2023, then grew by 0.8% to $1.5 billion in 2024, then gained by 1.93% to $1.5 billion in 2025, then declined by 15.4% to $1.3 billion in 2026.
• Business Quant data shows RARE's Liabilities and Shareholders Equity at $1.3 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.2 billion in Q3 2025.